The Serametrix Tetramer Assay measures T-cell activation to tumor antigens. Using patented tetramer technologies and reagents from the Ludwig Institute for Cancer Research (LICR), this assay measures a patient’s cellular immune response to specific panels of tumor antigens, and can reveal the relationship between T-cell activation and clinical outcome to immunotherapy (1,2).
The Serametrix Tetramer Assay includes study design, tetramer assay, and results with comprehensive analysis and interpretation. Disease-specific panels include:
For most disease panels it is possible to measure not only CD8+ cytotoxic T-cell responses but also CD4+ helper T-cells. In addition, the range of patient haplotypes that can be measured is increasing, with almost complete patient coverage for the leading cancer types.
To discuss ideas for your study or request a quote, click here.